Telomeres are specialized nucleoprotein structures composed of long arrays of TTAGGG repeats localized at the ends of human chromosomes able to maintain genome stability and integrity and to protect the cell from progressive DNA shortening during repeated division \[[@CR1]\]. Telomere biology has been more extensively studied in chronic myeloid leukemia (CML) than in any other blood cancer. Shorter telomeres have been associated with CML, disease progression, poor prognosis, higher Hasford score, and acquisition of cytogenetic aberrations \[[@CR2]--[@CR4]\]. As yet, no studies have considered the possible association between telomere length and treatment-free remission (TFR) after discontinuation of therapy with tyrosine kinase inhibitors (TKIs).

Thirty-two chronic-phase CML patients discontinued TKI treatment after achieving complete molecular remission (CMR) for at least 18 months. All patients received imatinib therapy for more than 24 months. Two patients underwent second-line treatment with nilotinib because of molecular relapse. The median follow-up after discontinuation was 30 months (range 18--60). A complete molecular response was defined as undetectable breakpoint cluster region-Abelson (BCR/ABL1) by real-time quantitative polymerase chain reaction (qRT-PCR) with a sensitivity of the assay corresponding to molecular response (MR)4 and MR4.5. Peripheral blood samples from 32 age- and sex-matched healthy individuals were used for control purposes. The relative telomere length (RTL) was determined by q-PCR according to the technique described by Cawthon in 2002 \[[@CR5]\] (Additional file [1](#MOESM1){ref-type="media"}). Age-corrected RTL (acRTL) represented the difference in telomere length between patients and age- and sex-matched controls.

The characteristics of 32 chronic phase CML patients are shown in Table [1](#Tab1){ref-type="table"}. Thirteen patients (41 %) showed loss of CMR. All relapsed patients regained CMR after restarting treatment with TKIs. The 36-month cumulative probability of TFR was 59.4 %. RTL was assessed at a mean of 26 months from discontinuation (range 20--30). RTL was assessed at a mean of 26 months from discontinuation (range 18--30). The majority of relapses occurred within 9 months of therapy interruption (mean 8.7 months, range 2--20). In these patients, RTL was assessed after relapse. Overall, median RTL was slightly shorter in patients than in controls (0.97 vs 1.05). The median value of acRTL in the CML cohort was 0.09 (range −0.26, +0.86). The Mann-Whitney *U* test showed shorter acRTL in TFR patients compared to patients with molecular relapse (mean ± SD = 0.01 ± 0.14 vs 0.20 ± 0.21; *p* = 0.01) (Additional file [2](#MOESM2){ref-type="media"}). Although the male gender was more frequent in TFR patients, we did not find any significant difference in telomere length between male and female. Patients were stratified according to the median value of acRTL ≤0.09. TFR was significantly higher in CML patients with acRTL ≤0.09 in comparison to those with longer telomeres (78.9 vs 30.8 %, *p* = 0.002) (Fig. [1](#Fig1){ref-type="fig"}).Table 1Characteristics of 32 CML patients according to treatment-free remission (TFR) or molecular relapse after imatinib discontinuationPatients in TFR no. 19 (59 %)Relapsed patients no. 13 (41 %)*p*Age at diagnosis (mean, range)74 (47--88)56 (37--77)0.004Leukocytes at diagnosis ×10^3^/uL (mean, range)50.47 (8.15--221)69 (19.8--263)nsPlatelets at diagnosis ×10^3^/uL (mean, range)472 (178--918)357 (171--695)nsMonths to CMR (median, range)28 (3--88)30 (6--93)nsMonths of TKIs (median, range)86 (24--127)84 (45--143)nsMonths of TKIs \>60 (no., %)1368.41292.3nsMale gender (no., %)1684.2861.5nsSokal risk (no., %) Low631.6861.5ns Intermediate1052.6323.1ns High315.8215.4nsFirst-line TKI treatment (no., %)1157.91184.6nsPrevious IFN treatment (no., %)842.1215.4nsImatinib first-line TKI treatment (no., %)1910013100nsNilotinib second-line TKI treatment (no., %)15.317.7nsAge-corrected relative telomere length (mean ± SD)0.01 ± 0.140.20 ± 0.210.01*pres* present, *CMR* complete molecular response, *TKIs* tyrosine kinase inhibitors, *IFN* interferon, *ns* not significant, *SD* standard deviationFig. 1Treatment-free remission (TFR) according to age-corrected relative telomere length (acRTL) ≥0.09 in 32 CML patients

Previous studies suggest a dual-step model for telomere length changes in CML. In the earlier phases, increased turnover of Philadelphia positive (Ph+) progenitors would result in telomere shortening, leading to genetic instability. Later, CML cells would escape senescence and apoptosis through upregulation of telomerase and restored telomere length. This would promote the occurrence of genetically unstable CML subclones with a selective growth advantage \[[@CR6]\]. Discontinuation of TKIs is the next hurdle to be overcome in the management of CML patients. Several factors have been identified as potentially capable of predicting durable TFR and hopefully definitive recovery \[[@CR7], [@CR8]\]. A significant correlation between younger age and molecular relapse was reported \[[@CR9]\]. In our study, CML patients had a slightly shorter telomere length than healthy controls and we found a statistically significant correlation between aging and telomere shortening. However, the most interesting finding was that TFR patients showed significantly shorter acRTL compared to molecular relapses. A possible explanation is that quiescent CML stem cells harboring longer telomeres somehow manage to escape senescence mechanisms and maintain a proliferative potential even after discontinuation of imatinib treatment, but this hypothesis should be supported by CML stem cell telomere assessment in patients with molecular response. Some limitations need to be noted in our study. First, the cohort of patients was relatively small and a longitudinal telomere assessment from diagnosis is lacking. Furthermore, we did not determine sorted myeloid compartment telomere length, but previous reports showed that no significant differences in CML telomere lengths are observed when comparing peripheral mononuclear blood cells, fractionated peripheral neutrophils, and non-fractionated bone marrow mononuclear cells \[[@CR10]\]. The present study is the first to suggest that patients with longer telomeres would seem to be more susceptible to relapse after TKI treatment.
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